Advertisement
Advertisement
TOPIC

Biomedicine: Companies

Related Topics:
Biomedicine: Companies
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
Alibaba’s Damo Academy was established in 2017, with recent focus areas including AI tools for cancer detection. Photo: Getty Images
Alibaba

Alibaba open-sources AI model that can detect cancer and nearly 150 conditions

Tested on nearly 40,000 real-world exams, the model outperformed most radiologists, according to a new study published in Science.

Biomedicine: Policy

Biomedicine powerhouse: China targets quarter of global first-in-class drugs

Biomedicine: Industry Trends

ByteDance spin-off Anew Labs raises US$290m amid AI drug design fundraising boom

videocam
Biomedicine: Industry Trends

GSK’s US$750 million cancer drug deal highlights China’s rise as biotech player

The acquisition is the latest in a string of major licensing deals involving Chinese biotechnology firms.

4
GSK has agreed a deal worth up to US$750 million to license a T-cell engager from a Chinese biotechnology firm. Photo: Reuters
Greater Bay Area

Data from Greater Bay Area residents to help improve healthcare policy: GSK

Executive says pharmaceutical company is investing in shared data infrastructure.

IPO

Hong Kong watchdog investigates Cloudbreak Pharma for ‘rigged’ IPO

Regulator cites ‘serious concerns’ about ‘artificial impression of demand’ in US-based company’s US$78 million listing in 2025.

Advertisement
Advertisement
Advertisement
Greater Bay Area

Hong Kong targets biomedicine powerhouse status in debut 5-year plan

Tied to the national strategy, the city’s first five-year blueprint doubles down on Greater Bay Area medical tech and healthcare cooperation.

Hong Kong Secretary for Health Lo Chung-mau speaking at the fifth Hong Kong International Biotechnology Conference and Exhibition. Photo: Handout
Technology

As China embraces AI, few US pharmaceutical execs bet on it for innovation

Survey finds drug companies planned to scale AI or had already done so, but few anticipated a ‘wholesale revolution’ from the tech.

videocam
China’s private sector

China needs monkeys: lab animal shortage could hinder biotech growth

As fundraising and out-licensing deals in China grow, so does demand for monkeys and other primates for testing.

IPO

More Chinese developers of brain-computer interfaces move towards IPOs

Arfysica and Neuracle aim for Star Market listings amid what a Morgan Stanley analyst calls the ‘early stage of a multi-year IPO upcycle’.

videocam
The firms join a broader trend of hi-tech firms flocking to the Shanghai Stock Exchange’s Nasdaq-style Star Market. Photo: Xinhua
Banking & finance

Why Asian investors are pouring capital into brain tech and surgical robots

Family offices and venture investors across Hong Kong and the wider region are reshaping portfolios to capture long-term biotech growth.

An orthopedic surgical robot is displayed at the 2026 World Robot Conference in Beijing on August 20. Photo: Xinhua
Banking & finance

US surgical robotics firm targets Hong Kong listing to tap mainland China market

Noah Medical expects to file application as early as next year, joining surge of tech listings tapping city’s international fundraising pool.

videocam
Artificial intelligence

Biomedicine | China thinks big on brain-computer interfaces

Launch of commercial BCI implantation, ahead of US, offers hope to millions with brain or spinal injuries as plans are made for the technology’s wider use.

Hong Kong stock market

China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial

The biliary tract cancer trial is the latest breakthrough for Akeso’s ivonescimab, which has also shown promise in treating some lung cancers.

China’s biopharmaceutical firms are increasingly looking to compete directly on the global market. Photo: Shutterstock
Hong Kong stock market

China rushes to develop Moderna-style cancer vaccines amid market frenzy

Chinese biotech firms are already working on more than 100 cancer vaccines. Now, many are seeing their shares surge amid Moderna’s breakthrough.

videocam
7
Chinese biotechnology firms are working on more than 100 cancer vaccine programmes, according to analysts. Photo: Shutterstock
Wuxi Biologics

WuXi Biologics posts 4.3% rise in first-half profit, defying biotech headwinds

Higher gross margins, surging projects and continued demand from North American markets help power the drug developer’s strong first-half performance.

Medicine

Overseas licensing has helped fuel China’s biotech profits. Will it last?

Out-licensing deals have overtaken IPOs as the primary lifeline for cash-starved Chinese drug makers, analysts say.

videocam
Advertisement
Advertisement
Advertisement
Hong Kong economy

Chinese tech, pharma firms eye Hong Kong as springboard for global expansion

Industry leaders highlight city’s international reach and expertise as state-owned drug maker considers Northern Metropolis project investment.

A general view of Guangzhou. The Hong Kong and Macau Affairs Office arranged a six-day trip spanning the Greater Bay Area. Photo: Eugene Lee
Science

Chinese stem cell therapy restores heart function in 90% of trial patients

Study finds patients injected with iPSC-derived heart muscle cells outperform control group on cardiac function tests after bypass surgery.

videocam
12
Biomedicine: Industry Trends

Patience needed before human gene therapy trials, Stanford expert says

Human testing could take up to five years to ramp up, but AI approaches will yield results in time, Karoly Nikolich says.

videocam
Science

Chinese ‘yeast factory’ boosts cancer drug production by 1,000 times

Turning point comes from cross-disciplinary collaboration, including across plant biochemistry, synthetic biology and protein engineering.

videocam
Researchers have engineered brewer’s yeast to produce catharanthine – the direct precursor to the cancer treatment vinblastine. Photo: Getty Images/iStockphoto
China’s private sector

China’s drug firms set to compete on the world stage, analysts say

Amid systemic efficiency and a wave of innovation, the country’s biotech sector is expanding at a pace that has caught the market off guard.

4
With an efficiency edge that transcends simple cost advantages, China is set to see the emergence of a home-grown drug giant capable of competing with global players. Photo: Shutterstock
China technology

China races to develop brain-computer interfaces that can be inserted in minutes

The technology – which allows patients to control digital devices using their thoughts – can be implanted like a stent in just a few minutes.

China’s private sector

Global pharma giants turn to Chinese biotech to tap innovation, valuation growth

The foreign investments can help Chinese companies grow and compete on the global stage, according to Citic Securities.

China’s private sector

Sugar for the pill: US$8b fund boosts Hong Kong’s biotech hub ambitions

Hong Kong Investment Corporation is stepping up its efforts to position itself amid Beijing’s challenge to US pharmaceutical dominance.

Clara Chan Ka-chai, CEO of Hong Kong Investment Corporation (HKIC) Photo: Enoch Yiu
Banking & finance

China biotech giant WuXi AppTec sees first-half earnings surge amid US scrutiny

Strong orders for weight-loss and diabetes treatments drive firm’s growth, despite being caught up in US efforts to curb China’s ambitions.

Wuxi AppTec, Asia’s largest provider of contract pharmaceutical research, surpassed analysts’ expectations in the first half of the year. Photo: Handout
Science

China biotech sector fears policy backlash after girl dies in gene-editing trial

Scientist says child’s death reveals ‘serious failures in risk assessment, transparency and institutional oversight’.

videocam
Banking & finance

As weight-loss drug orders surge, global funds pile into China’s WuXi AppTec

Pharmaceutical contractor’s GLP-1 programmes and surging stock gains have made it a magnet for global investors.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement